Introduction: Overproduction of immunoglobulin E (IgE) by a subset of B cells plays a key role
INTRODUCTION
Elevation of serum immunoglobulin E (IgE) level is correlated with atopic diseases such as allergic rhinitis and allergic asthma.
(1) Circulated IgE in the blood binds to the high-affinity IgE receptor (FcƐRI) on the surface of mast cells positioned along the mucosal lining and underneath the skin during an allergic response. IgE-mediated mast cell degranulation also results in the release of newly synthesised inflammatory cytokines and chemokines, including IL-4, IL-5, IL-6, TNF, MCP-1 and MIP-1, and thus plays a role in the late phase of allergic responses. (2) Therefore, IgE is usually used as a natural target for anti-allergic therapy. Indeed, anti-IgE monoclonal antibodies (mAbs) have successfully been developed for the treatment of IgE-mediated allergic disorders. (3) (4) (5) (6) (7) It has been demonstrated that anti-IgE mAbs attenuate both early-and late-phase asthmatic responses, improving both the symptom score and peak expiratory flow in patients with allergic asthma. (8) (9) (10) To benefit from this treatment, however, patients required the injection of a high dose of anti-IgE antibody (150-300 mg/injection) every 2-4 weeks. (11) Despite a near-complete suppression of free IgE, a prolonged and substantial rise in total IgE, in the form of IgE-anti-IgE complexes, was observed in patients who received anti-IgE antibody, (3) suggesting that IgE synthesis could not be stopped by the treatment. (9, 12, 13) Thus, the direct inhibition of IgE-producing cells by IgE-specific cytotoxic T lymphocytes (CTLs) may be an alternative approach to the long-term treatment of allergic disorders.
CTLs play an essential role in immunity against viral and intracellular pathogens by recognising antigenic peptides in the context of major histocompatibility complex (MHC) Class I molecules. (14) Previously, we showed that Drosophila-derived artificial antigen-presenting cells (aAPC) can be used to generate CTLs specific for tumour-associated antigenic peptides in vitro,
and that the adoptive transfer of these CTLs inhibits tumour cell growth in vivo. (15) Therefore, we hypothesised that adoptive transfer of these IgE-specific CTLs should also be able to lyse IgE-producing B cells in vivo and consequently lead to inhibition of IgE-mediated pathology.
This study aimed to evaluate whether IgE antigenic peptide-specific CTLs can be generated in vitro and to test if these CTLs could inhibit IgE responses in vivo. Using an established aAPC system, (16) we successfully generated IgE-specific CTLs in vitro, the adoptive transfer of which efficiently inhibited IgE responses and airway inflammation in an asthmatic mouse model. and CD80 (also B7-1) were generated and maintained as previously described. (16) The MHC Class I stabilisation assay was applied, also as previously described. (17) 
METHODS

C57BL/6J (B6)
The mouse model of allergic asthma was generated as indicated in Fig. 1 GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA) was used for statistical analysis. Mean methacholine dose-response curves for each experimental group were compared using two-way analysis of variance. All data was presented as mean ± standard deviation.
Student's t-test was used for all comparisons. A p-value < 0.05 or < 0.01 was considered statistically significant or extremely significant, respectively.
RESULTS
The amino acid sequence of the constant region of IgE was analysed for 9-mer peptide sequences (Table I) . Peptide sequence Score (Table I ).
The ability of the IgE-derived peptides to elicit CTL responses was initially evaluated in vitro. As previously described, (16) (Figs. 4a & b) . Contrarily, the IFN- -/-mice-derived CTLs specifically killed the target cells (Fig. 4a ) and showed a similar inhibition effect on IgE responses in vivo to that of wild type (WT) CTLs (Fig. 4b) . These results suggested that the expression of PF, rather than IFN-, was required for CTL activity, and that the validated inhibition of IgE response by IgE-specific CTLs most likely resulted from PF-mediated killing of IgE-producing cells.
CTLs, as effector cells, recognise peptides presented by peptide-MHC complexes on target cells. Therefore, we investigated whether the activity of IgE-specific CTLs was dependent on MHC Class I molecule expression on target cells. IgE-specific peptide IgEp44 is restricted by MHC Class I molecule D b and induces specific CTLs (Fig. 4c) . When an anti-D b mAb was added, it completely blocked the recognition of IgEp44/D b complexes and the cytolysis of target cells induced by IgEp44-specific CTLs (Fig. 4c) . Hence, the killing activity of IgE-specific CTLs was dependent on the interaction of T cell receptors on CTLs and peptide-MHC complexes expressed on target cells. To further examine the influence of MHC Class I molecule expression on the function of IgE-specific CTLs in vivo, we pre-sensitised WT B6 or 2m -/-mice with OVA. (25) IgE responses were induced in 2m -/-mice as well as WT B6 mice (Fig. 4d) . However, adoptively transferred IgE-specific CTLs inhibited IgE responses only in WT mice rather than in 2m -/-mice. Thus, the activity of IgE-specific CTLs is dependent on the expression of MHC Class I molecules, and the recognition of peptide-MHC Class I complexes on target cells is required for the function of IgE-specific CTLs in vivo.
We investigated the long-term in vivo effect of adoptively transferred IgE-specific CTLs in an asthmatic mouse model. Pre-sensitised mice were randomly divided into two groups: one was given IgE-specific CTLs (i.e. CTL group), while the other received PBS (i.e. PBS group) during the initial challenge. At the time intervals indicated, both groups of mice were re-challenged with OVA, and serum IgE was measured one week after each challenge. Before the IgE-specific CTL treatment, IgE levels were elevated in both groups (Fig. 5a ). However, as early as two weeks following CTL treatment, IgE responses were markedly inhibited when the mice were re-challenged with OVA (data not shown). The inhibition remained for up to six months in the CTL group (Fig. 5a ). In the PBS group, IgE responses recovered four months after receiving CTL treatment (data not shown), and these mice were administered a second IgE-specific CTL treatment (Fig. 5b) . Again, IgE responses of both groups were reduced and the resultant low levels of IgE remained up to four months following CTL retreatment (Fig. 5b) . In summary, IgE-specific CTLs induced a sustained inhibition of IgE responses in vivo, and those mice with a recovering IgE response could respond to a second CTL treatment with reduced levels of IgE following the antigen challenge.
Since IgE-specific CTLs effectively inhibited IgE responses in a mouse model of allergic asthma (Figs. 2-5 ), we investigated whether airway inflammation could be reduced by IgE-specific CTL treatment. Pre-sensitised mice were treated with indicated doses of IgE-specific CTLs during the intranasal challenges. Two weeks after CTL treatment, both total serum IgE and OVA-specific IgE levels were measured. The IgE level decreased about 50% in the mice that received 5  10 6 IgE-specific CTLs but was inhibited more than 70% in the mice receiving twice that dose of CTLs (Fig. 6a) . Five weeks after the CTL treatment, the mice were re-challenged intranasally with OVA every other day, for a total of three times. Mouse BAL fluid was examined 24 hours after the final challenge. Consistent with the inhibition of IgE responses, inflammatory cells in the BAL were dramatically reduced in the CTL-treated mice;
this effect was most dramatic for eosinophils ( Fig. 6b ; partial data not shown). As a major chemokine for eosinophils, eotaxin in the BAL was also measured. The concentration of eotaxin, as well as eosinophils, was significantly reduced in the CTL-treated mice (Fig. 6b) . The reduction of eosinophils and eotaxin in the BAL was dependent on the dose of administered CTLs and correlated with the inhibition of IgE responses by specific CTLs (Figs. 6a & b) . Thus, IgE-specific CTLs effectively inhibited both IgE responses and airway inflammation in a dose-dependent manner.
The effect of IgE-specific CTLs on airway inflammation was further confirmed with examination of lung histology ( The hallmarks of asthma are airway hyperresponsiveness (AHR) and airway inflammation. (26) Since IgE-specific CTLs could inhibit IgE responses and reduce airway inflammation, we investigated whether CTL treatment could reduce AHR. Sensitised mice were treated with IgE-specific anti-IgE CTLs and re-challenged as described in Fig. 6b . 24 hours after the last challenge, AHR was assessed with Penh measurements in response to increasing doses of nebulised methacholine using whole body plethysmographs. (27, 28) In the absence of IgE-specific CTL treatment, the challenge of pre-sensitised mice induced AHR to an increasing concentration of nebulised methacholine (Figs. 6d & e) . However, the induced AHR was markedly reduced in the CTL-treated mice, while the control CTLs had little effect (Fig. 6d) . The AHR was significantly reduced by IgE-specific CTLs to a level similar to that in normal mice (Fig. 6e) .
Thus, IgE-specific CTLs effectively reduced both airway inflammation and AHR in pre-sensitised mice.
DISCUSSION
Immunotherapy has been developed to fight diseases such as cancer, autoimmune diseases and Alzheimer's disease. (29) (30) (31) In this study, we demonstrated that one kind of T cell-based immunotherapy CTLs specific for IgE, a non-tumour self-antigen expressed on a subset of B cells, can be generated in vitro with aAPCs. Eosinophilic inflammation in the lung is an important feature of allergic asthma. (33) Adoptively transferred IgE-specific CTLs could inhibit both IgE responses and airway eosinophilic inflammation in the animal model of asthma. The inhibition efficiency depended on the dose of IgE-specific CTLs transferred and was directly correlated with the reduction of airway inflammation. This data indicates that specific CTL-mediated inhibition of IgE responses leads to the reduction of airway eosinophilic inflammation.
Anti-IgE antibodies that compete in binding to IgE at the same site as its FcƐRI have been developed for the treatment of asthma. (3, 4, 34) These antibodies inhibit IgE effector function by blocking IgE binding to its high affinity receptors expressed on mast cells and basophils, consequently blocking the inflammatory cascade induced by crosslinking of receptor-bound IgE.
One of them, omalizumab (Xolair), has been developed and used successfully for the treatment of patients with moderate to severe asthma. (3, 4, 11, 34, 35) Xolair has been demonstrated to improve symptoms and reduce rescue medication and corticosteroid use in patients with allergic asthma. (34, 36) However, despite the near-complete reduction of free IgE by the anti-IgE antibody, the total IgE level (IgE-anti-IgE complexes) continued to rise and was shown to be fivefold higher in patients who received anti-IgE for 16 weeks. (3, 13) Within weeks after discontinuing the treatment, free IgE level returned to base level, (11) and most of the patients needed treatment with an anti-IgE antibody every 2-4 weeks for an extended period. In our study, IgE-specific CTLs recognised IgE-derived peptides presented by MHC Class I molecules. A single IgE-specific CTL treatment was sufficient to inhibit IgE responses to antigenic challenge for up to six months (Fig. 5 ), suggesting that a direct inhibition or elimination of IgE-producing B cells and plasma cells by IgE-specific CTLs, could be a more efficient approach to the treatment of allergic asthma and some other allergic disorders.
Additionally, IgE-specific CTLs enhanced IgG2a responses to the tested antigens in the sensitised mouse model (Fig. 3c) . This enhancement of IgG2a responses appears to be unspecific for IgE-specific CTLs, because the control CTLs that did not inhibit IgE responses could also enhance the IgG2a responses (Fig. 3c) . cytokine production profile. In this study, IgE-specific CTLs were stimulated with APC expressing both CD54 and CD80. As expected, these CTLs express IL-10 rather than IL-4. It has been reported that IL-10 can be used to ameliorate allergen-induced asthma, airway hyper-reactivity and inflammation. (38) (39) (40) (41) Thus, regulation of cytokine production by CTLs could be an additional strategy for regulation of immune response in vivo by IgE-specific CTLs. . Anti-IgE CTLs were generated as described in Fig. 1 , and control CTLs were generated with an influenza nuclear protein antigenic peptide. Two weeks after the second immunisation, the mice were challenged with ovalbumin intranasally every other day, for a total of three times. IgE-specific or control CTLs (5  10 6 ) were given intravenously one day after each challenge. There were five mice in each group. PBS: phosphate-buffered saline 
